

**ANIMAL WELFARE AND ETHICAL REVIEW BODY**

**Minutes of the meeting held on 23 January 2020**

Present:

[REDACTED]

Apologies:

[REDACTED]

**1. Minutes**

*Agreed:* That the minutes of the meeting held on 14 November 2019 were approved subject to correction of the dates for future meetings.

**2. Update on applications outstanding from previous meetings**

**2.1. [REDACTED], Melanoma Formation, Immune Responses & Evaluating Novel Therapeutic Approaches & Agents.**

To report: Revisions submitted.

**2.2. [REDACTED], Mechanistic Insight Into/Assessment of Novel Therapies for/Preeclampsia & Fetal Growth Restriction.**

To report: The Home Office requested minor changes.

**2.3. [REDACTED], Breeding & Maintenance of Genetically Altered Zebrafish**

To report: Revisions still to be submitted for Establishment Licence Holder approval

**2.4. [REDACTED], The Role of Inflammation in Cerebrovascular Disease.**

To report: Amendment submitted to the Home Office and granted.

**2.5. [REDACTED], Defining Critical Regulatory Pathways Controlling Local & Distal Immune Responses During Health & Inflammation of Barrier Surfaces.**

To report: Home Office has fed back on the submitted draft and [REDACTED] needs to make changes and submit these back to the executive committee.

**2.6. [REDACTED], Mechanisms of Diabetes-Associated Heart Disease.**

To report: [REDACTED] will be submitting a revised application for consideration at a future AWERB meeting.

**2.7. [REDACTED], The Aetiology of Diabetic Neuropathy.**

To report: Revisions still to be submitted for Establishment Licence Holder approval.

**3. Mid-term review - not requiring licence holder attendance at meeting**

**3.1. [REDACTED], Preclinical evaluation of cancer therapeutics.**

*Considered:* A completed AWERB review form.

- Discussed:*
- The Project Licence holder had completed the form to a high standard which allowed the committee to fully consider the current status of the work on the licence.
  - The Committee were reassured that the earlier deaths on the licence were no longer happening due to an improvement in the method for assessing the occurrence and severity of pain.
  - The Committee were reassured that the severity classification of Protocol 1 (Severe) was justified and it did not require an amendment submitting to the Home Office to change it to Moderate.

*Actions:* The AWERB Secretary should feedback to the licence holder on the points discussed above.

*Outcome:* The AWERB support the ongoing work under this licence.

**4. Report on licences processed from 25/10/2019 to 10/01/2020**

The following amendments were approved by the executive committee.

**4.1. Amendments to Project Licences**

[REDACTED], Cardiac Conduction System in Health & Disease.

**Noted:** [REDACTED] was impressed with how the animals are nurtured and trained in this licence.

**Action:** [REDACTED] will approach the licence holder to ask if there are pictures that can be circulated to the AWERB members.

[REDACTED], Understanding Vision & Developing Therapies for Blindness.

